Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Guidelines
  • Published:

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia

Abstract

These guidelines on the management of HSV, VZV and EBV infection in patients with hematological malignancies and after SCT were prepared by the European Conference on Infections in Leukemia following a predefined methodology. A PubMed search was conducted using the appropriate key words to identify studies pertinent to management of HSV, VZV and EBV infections. References of relevant articles and abstracts from recent hematology and SCT scientific meetings were also reviewed. Prospective and retrospective studies identified from the data sources were evaluated, and all data deemed relevant were included in this analysis. The clinical and scientific background was described and discussed, and the quality of evidence and level of recommendation were graded according to the Centers for Disease Control criteria.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Georg Maschmeyer, Lars Bullinger, … Thierry Calandra

References

  1. Cordonnier C . The first European conference on infections in leukaemia: why and how? Eur J Cancer Suppl 2007; 5: 2–4.

    Google Scholar 

  2. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1–125, CE1-7.

    Google Scholar 

  3. Bustamante CI, Wade JC . Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 1991; 9: 1903–1915.

    CAS  PubMed  Google Scholar 

  4. Reusser P . Opportunistic viral infections. Infect Dis 2004; 2: 1169–1181.

    Google Scholar 

  5. Whitley RJ, Roizman B . Herpes simplex virus infections. Lancet 2001; 357: 1513–1518.

    CAS  PubMed  Google Scholar 

  6. Meyers JD, Flournoy N, Thomas ED . Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142: 338–346.

    CAS  PubMed  Google Scholar 

  7. Saral R, Burns WH, Prentice HG . Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 1984; 13: 645–660.

    CAS  PubMed  Google Scholar 

  8. Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983; 99: 773–776.

    CAS  PubMed  Google Scholar 

  9. Reusser P . Management of viral infections. Supportive Care in Cancer: A Handbook for Oncologists 1999; 2: 87–112.

    Google Scholar 

  10. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73 (1A): 229–235.

    CAS  PubMed  Google Scholar 

  11. Spencer GD, Hackman RC, McDonald GB, Amos DE, Cunningham BA, Meyers JD et al. A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 1986; 42: 602–607.

    CAS  PubMed  Google Scholar 

  12. Meyers JD, Flournoy N, Thomas ED . Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982; 4: 1119–1132.

    CAS  PubMed  Google Scholar 

  13. Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L . Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med 1982; 97: 813–820.

    CAS  PubMed  Google Scholar 

  14. Wingard JR, Mellits ED, Sostrin MB, Chen DY, Burns WH, Santos GW et al. Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. Medicine (Baltimore) 1988; 67: 175–186.

    CAS  Google Scholar 

  15. Ballen KK, Donadio D, Bouloux C, McCarthy P, Weinstein H, Antin JH . Herpes simplex virus and neutropenia following bone marrow transplantation. Transplantation 1992; 54: 553–555.

    CAS  PubMed  Google Scholar 

  16. Kaufman B, Gandhi SA, Louie E, Rizzi R, Illei P . Herpes simplex virus hepatitis: case report and review. Clin Infect Dis 1997; 24: 334–338.

    CAS  PubMed  Google Scholar 

  17. Mommeja-Marin H, Lafaurie M, Scieux C, Galicier L, Oksenhendler E, Molina JM . Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults. Clin Infect Dis 2003; 37: 1527–1533.

    PubMed  Google Scholar 

  18. Ferrari A, Luppi M, Potenza L, Riva G, Morselli M, Imovilli A et al. Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature. Leukemia 2005; 19: 2019–2021.

    CAS  PubMed  Google Scholar 

  19. Whitley RJ, Gnann Jr JW . Acyclovir: a decade later. N Engl J Med 1992; 327: 782–789.

    CAS  PubMed  Google Scholar 

  20. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS . Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63–67.

    CAS  PubMed  Google Scholar 

  21. Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983; 2: 706–708.

    CAS  PubMed  Google Scholar 

  22. Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983; 287: 384–388.

    CAS  Google Scholar 

  23. Shepp DH, Dandliker PS, Flournoy N, Meyers JD . Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987; 43: 654–658.

    CAS  PubMed  Google Scholar 

  24. Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J . Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. Br Med J 1995; 310: 1169–1172.

    CAS  Google Scholar 

  25. Zaia JA . Viral infections associated with bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 603–623.

    CAS  PubMed  Google Scholar 

  26. Wade JC . Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993; 7: 293–315.

    CAS  PubMed  Google Scholar 

  27. Balfour Jr HH . Antiviral drugs. N Engl J Med 1999; 340: 1255–1268.

    CAS  PubMed  Google Scholar 

  28. Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF et al. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma 2004; 45: 2215–2219.

    CAS  PubMed  Google Scholar 

  29. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD . Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96: 265–269.

    CAS  PubMed  Google Scholar 

  30. Shepp DH, Newton BA, Dandliker PS, Flournoy N, Meyers JD . Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 1985; 102: 783–785.

    CAS  PubMed  Google Scholar 

  31. Wade JC, McLaren C, Meyers JD . Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983; 148: 1077–1082.

    CAS  PubMed  Google Scholar 

  32. McLaren C, Chen MS, Ghazzouli I, Saral R, Burns WH . Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother 1985; 28: 740–744.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour Jr HH . Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112: 416–422.

    CAS  PubMed  Google Scholar 

  34. Verdonck LF, Cornelissen JJ, Smit J, Lepoutre J, de Gast GC, Dekker AW et al. Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. Bone Marrow Transplant 1993; 11: 177–179.

    CAS  PubMed  Google Scholar 

  35. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link D, Locasciulli A et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 813–817.

    CAS  PubMed  Google Scholar 

  36. Reusser P . Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996; 33: 235–248.

    CAS  PubMed  Google Scholar 

  37. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD . Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162: 244–248.

    CAS  PubMed  Google Scholar 

  38. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW . Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000; 181: 2055–2058.

    CAS  PubMed  Google Scholar 

  39. Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31: 927–935.

    CAS  PubMed  Google Scholar 

  40. Blot N, Schneider P, Young P, Janvresse C, Dehesdin D, Tron P et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000; 26: 903–905.

    CAS  PubMed  Google Scholar 

  41. Bryant P, Sasadeusz J, Carapetis J, Waters K, Curtis N . Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. Pediatr Infect Dis J 2001; 20: 1083–1086.

    CAS  PubMed  Google Scholar 

  42. Venard V, Dauendorffer JN, Carret AS, Corsaro D, Edert D, Bordigoni P et al. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. Pathol Biol (Paris) 2001; 49: 553–558.

    CAS  Google Scholar 

  43. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M . Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196: 266–270.

    CAS  PubMed  Google Scholar 

  44. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–296.

    CAS  PubMed  Google Scholar 

  45. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM . Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med 1989; 111: 893–899.

    CAS  PubMed  Google Scholar 

  46. Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S . Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161: 711–715.

    CAS  PubMed  Google Scholar 

  47. Oliver NM, Collins P, Van der Meer J, Van't Wout JW . Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents Chemother 1989; 33: 635–640.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Hill EL, Hunter GA, Ellis MN . In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991; 35: 2322–2328.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325: 551–555.

    CAS  PubMed  Google Scholar 

  50. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD . Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992; 166: 473–479.

    CAS  PubMed  Google Scholar 

  51. Donn SM, Dickerman JD . Fatal recurrent varicella in a child with acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1981; 3: 183–185.

    CAS  PubMed  Google Scholar 

  52. Dowell SF, Bresee JS . Severe varicella associated with steroid use. Pediatrics 1993; 92: 223–228.

    CAS  PubMed  Google Scholar 

  53. Hill G, Chauvenet AR, Lovato J, McLean TW . Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics 2005; 116: e525–e529.

    PubMed  Google Scholar 

  54. Novelli VM, Brunell PA, Geiser CF, Narkewicz S, Frierson L . Herpes zoster in children with acute lymphocytic leukemia. Am J Dis Child 1988; 142: 71–72.

    CAS  PubMed  Google Scholar 

  55. Atkinson K, Meyers JD, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47–50.

    CAS  PubMed  Google Scholar 

  56. Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD et al. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. Bone Marrow Transplant 1999; 23: 469–474.

    CAS  PubMed  Google Scholar 

  57. Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219–230.

    CAS  PubMed  Google Scholar 

  58. Callum JL, Brandwein JM, Sutcliffe SB, Scott JG, Keating A . Influence of total body irradiation on infections after autologous bone marrow transplantation. Bone Marrow Transplant 1991; 8: 245–251.

    CAS  PubMed  Google Scholar 

  59. Christiansen NP, Haake RJ, Hurd DD . Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991; 7: 435–437.

    CAS  PubMed  Google Scholar 

  60. Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277–283.

    CAS  PubMed  Google Scholar 

  61. Kawasaki H, Takayama J, Ohira M . Herpes zoster infection after bone marrow transplantation in children. J Pediatr 1996; 128: 353–356.

    CAS  PubMed  Google Scholar 

  62. Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197.

    CAS  PubMed  Google Scholar 

  63. Leung TF, Chik KW, Li CK, Lai H, Shing MM, Chan PK et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 25: 167–172.

    CAS  PubMed  Google Scholar 

  64. Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B . Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153: 840–847.

    CAS  PubMed  Google Scholar 

  65. Maltezou HC, Kafetzis DA, Abisaid D, Mantzouranis EC, Chan KW, Rolston KV . Viral infections in children undergoing hematopoietic stem cell transplant. Pediatr Infect Dis J 2000; 19: 307–312.

    CAS  PubMed  Google Scholar 

  66. Nakayama H, Okamura J, Ohga S, Miyazaki C, Matsuzaki A, Ikuno Y et al. Herpes zoster in children with bone marrow transplantation: report from a single institution. Acta Paediatr Jpn 1995; 37: 302–307.

    CAS  PubMed  Google Scholar 

  67. Novitzky N, Rouskova A . Infectious complications following T-cell depleted hematopoietic stem-cell transplantation. Cytotherapy 2001; 3: 165–173.

    CAS  PubMed  Google Scholar 

  68. Offidani M, Corvatta L, Olivieri A, Mele A, Brunori M, Montanari M et al. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation. Clin Infect Dis 2001; 32: 1414–1422.

    CAS  PubMed  Google Scholar 

  69. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R . Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424–1427.

    CAS  PubMed  Google Scholar 

  70. Sempere A, Sanz GF, Senent L, de la Rubia J, Jarque I, Lopez F et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495–498.

    CAS  PubMed  Google Scholar 

  71. Takaue Y, Okamoto Y, Kawano Y, Suzue T, Abe T, Saito SI et al. Regeneration of immunity and varicella-zoster virus infection after high-dose chemotherapy and peripheral blood stem cell autografts in children. Bone Marrow Transplant 1994; 14: 219–223.

    CAS  PubMed  Google Scholar 

  72. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S . The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 1065–1069.

    CAS  PubMed  Google Scholar 

  73. Tzeng CH, Liu JH, Fan S, Wang SY, Wang SR, Chen KY et al. Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation. J Formos Med Assoc 1995; 94: 313–317.

    CAS  PubMed  Google Scholar 

  74. Wacker P, Hartmann O, Benhamou E, Salloum E, Lemerle J . Varicella-zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989; 4: 191–194.

    CAS  PubMed  Google Scholar 

  75. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM . Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992; 165: 119–126.

    CAS  PubMed  Google Scholar 

  76. Tomonari A, Iseki T, Takahashi S, Ooi J, Takasugi K, Shimohakamada Y et al. Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan. Br J Haematol 2003; 122: 802–805.

    PubMed  Google Scholar 

  77. Locksley RM, Flournoy N, Sullivan KM, Meyers JD . Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172–1181.

    CAS  PubMed  Google Scholar 

  78. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A . Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657–664.

    CAS  PubMed  Google Scholar 

  79. Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996–2005. Medicine (Baltimore) 2007; 86: 324–333.

    Google Scholar 

  80. Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10: 90–98.

    CAS  PubMed  Google Scholar 

  81. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071–3077.

    CAS  PubMed  Google Scholar 

  82. Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP et al. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982; 60: 714–720.

    CAS  PubMed  Google Scholar 

  83. Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001; 86: 1075–1086.

    CAS  PubMed  Google Scholar 

  84. Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 281–289.

    PubMed  Google Scholar 

  85. David DS, Tegtmeier BR, O'Donnell MR, Paz IB, McCarty TM . Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. Am J Gastroenterol 1998; 93: 810–813.

    CAS  PubMed  Google Scholar 

  86. Suwabe H, Yabe H, Tsutsumi Y . Relapsing hemorrhagic varicella. Pathol Int 1996; 46: 605–609.

    CAS  PubMed  Google Scholar 

  87. Balfour Jr HH, McMonigal KA, Bean B . Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983; 12 (Suppl B): 169–179.

    PubMed  Google Scholar 

  88. Muller I, Aepinus C, Beck R, Bultmann B, Niethammer D, Klingebiel T . Noncutaneous varicella-zoster virus (VZV) infection with fatal liver failure in a child with acute lymphoblastic leukemia (ALL). Med Pediatr Oncol 2001; 37: 145–147.

    CAS  PubMed  Google Scholar 

  89. Rogers SY, Irving W, Harris A, Russell NH . Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant 1995; 15: 805–807.

    CAS  PubMed  Google Scholar 

  90. Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC . Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant 2006; 37: 73–80.

    CAS  PubMed  Google Scholar 

  91. McCluggage WG, Fox JD, Baillie KE, Coyle PV, Jones FG, O'Hara MD . Varicella zoster gastritis in a bone marrow transplant recipient. J Clin Pathol 1994; 47: 1054–1056.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Takatoku M, Muroi K, Kawano-Yamamoto C, Nagai T, Komatsu N, Ozawa K . Involvement of the esophagus and stomach as a first manifestation of varicella zoster virus infection after allogeneic bone marrow transplantation. Intern Med 2004; 43: 861–864.

    PubMed  Google Scholar 

  93. Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y . Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir. Int J Hematol 2007; 85: 242–245.

    CAS  PubMed  Google Scholar 

  94. Leena M, Ville V, Veli-Jukka A . Visceral varicella zoster virus infection after stem cell transplantation: a possible cause of severe abdominal pain. Scand J Gastroenterol 2006; 41: 242–244.

    PubMed  Google Scholar 

  95. Ishizaki Y, Tezuka J, Ohga S, Nomura A, Suga N, Kuromaru R et al. Quantification of circulating varicella zoster virus-DNA for the early diagnosis of visceral varicella. J Infect 2003; 47: 133–138.

    PubMed  Google Scholar 

  96. Szabo F, Horvath N, Seimon S, Hughes T . Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia. Bone Marrow Transplant 2000; 26: 231–233.

    CAS  PubMed  Google Scholar 

  97. Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK . Disseminated zoster, hyponatraemia, severe abdominal pain and leukaemia relapse: recognition of a new clinical quartet after bone marrow transplantation. Br J Dermatol 2003; 149: 862–865.

    CAS  PubMed  Google Scholar 

  98. Walton RC, Reed KL . Herpes zoster ophthalmicus following bone marrow transplantation in children. Bone Marrow Transplant 1999; 23: 1317–1320.

    CAS  PubMed  Google Scholar 

  99. Leveque N, Galambrun C, Najioullah F, Bleyzac N, Pages MP, Bertrand Y . Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions. J Med Virol 2006; 78: 514–516.

    PubMed  Google Scholar 

  100. Fukuno K, Tomonari A, Takahashi S, Ooi J, Takasugi K, Tsukada N et al. Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia. Int J Hematol 2006; 84: 79–82.

    PubMed  Google Scholar 

  101. Sadick NS, Swenson PD, Kaufman RL, Kaplan MH . Comparison of detection of varicella-zoster virus by the Tzanck smear, direct immunofluorescence with a monoclonal antibody, and virus isolation. J Am Acad Dermatol 1987; 17: 64–69.

    CAS  PubMed  Google Scholar 

  102. Oranje AP, Folkers E . The Tzanck smear: old, but still of inestimable value. Pediatr Dermatol 1988; 5: 127–129.

    CAS  PubMed  Google Scholar 

  103. Gleaves CA, Lee CF, Bustamante CI, Meyers JD . Use of murine monoclonal antibodies for laboratory diagnosis of varicella-zoster virus infection. J Clin Microbiol 1988; 26: 1623–1625.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Coffin SE, Hodinka RL . Utility of direct immunofluorescence and virus culture for detection of varicella-zoster virus in skin lesions. J Clin Microbiol 1995; 33: 2792–2795.

    CAS  PubMed  PubMed Central  Google Scholar 

  105. Chan EL, Brandt K, Horsman GB . Comparison of Chemicon SimulFluor direct fluorescent antibody staining with cell culture and shell vial direct immunoperoxidase staining for detection of herpes simplex virus and with cytospin direct immunofluorescence staining for detection of varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8: 909–912.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Kido S, Ozaki T, Asada H, Higashi K, Kondo K, Hayakawa Y et al. Detection of varicella-zoster virus (VZV) DNA in clinical samples from patients with VZV by the polymerase chain reaction. J Clin Microbiol 1991; 29: 76–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Sauerbrei A, Eichhorn U, Schacke M, Wutzler P . Laboratory diagnosis of herpes zoster. J Clin Virol 1999; 14: 31–36.

    CAS  PubMed  Google Scholar 

  108. Kalpoe JS, Kroes AC, Verkerk S, Claas EC, Barge RM, Beersma MF . Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation. Bone Marrow Transplant 2006; 38: 41–46.

    CAS  PubMed  Google Scholar 

  109. de Jong MD, Weel JF, van Oers MH, Boom R, Wertheim-van Dillen PM . Molecular diagnosis of visceral herpes zoster. Lancet 2001; 357: 2101–2102.

    CAS  PubMed  Google Scholar 

  110. Gelb LD, Dohner DE, Gershon AA, Steinberg SP, Waner JL, Takahashi M et al. Molecular epidemiology of live, attenuated varicella virus vaccine in children with leukemia and in normal adults. J Infect Dis 1987; 155: 633–640.

    CAS  PubMed  Google Scholar 

  111. Tipples GA, Safronetz D, Gray M . A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains. J Virol Methods 2003; 113: 113–116.

    CAS  PubMed  Google Scholar 

  112. Chen PY, Chu HY, Shian WJ, Shu SG, Chi CS . Varicella-zoster virus infection in children with malignancy. Zhonghua Yi Xue Za Zhi (Taipei) 1994; 54: 417–423.

    CAS  Google Scholar 

  113. Miliauskas JR, Webber BL . Disseminated varicella at autopsy in children with cancer. Cancer 1984; 53: 1518–1525.

    CAS  PubMed  Google Scholar 

  114. Weinstock DM, Boeckh M, Boulad F, Eagan JA, Fraser VJ, Henderson DK et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol 2004; 25: 603–608.

    PubMed  Google Scholar 

  115. Gershon AA, Steinberg SP . Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis 1990; 161: 661–666.

    CAS  PubMed  Google Scholar 

  116. LaRussa P, Steinberg S, Meurice F, Gershon A . Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis 1997; 176: 1072–1075.

    CAS  PubMed  Google Scholar 

  117. Ross AH . Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267: 369–376.

    CAS  PubMed  Google Scholar 

  118. Seiler HE . A study of herpes zoster particularly in its relationship to chickenpox. J Hyg (Lond) 1949; 47: 253–262.

    CAS  Google Scholar 

  119. Gustafson TL, Lavely GB, Brawner Jr ER, Hutcheson Jr RH, Wright PF, Schaffner W . An outbreak of airborne nosocomial varicella. Pediatrics 1982; 70: 550–556.

    CAS  PubMed  Google Scholar 

  120. Pediatrics AAo. Varicella-zoster infections. Red book 2006 Report of the Committee on Infectious Diseases. 2006; 27th edn: 711–717.

  121. Geiser CF, Bishop Y, Myers M, Jaffe N, Yankee R . Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin. Cancer 1975; 35: 1027–1030.

    CAS  PubMed  Google Scholar 

  122. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 737–743.

    CAS  PubMed  Google Scholar 

  123. Orenstein WA, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, Halsey NA et al. Prophylaxis of varicella in high-risk children: dose–response effect of zoster immune globulin. J Pediatr 1981; 98: 368–373.

    CAS  PubMed  Google Scholar 

  124. Suga S, Yoshikawa T, Ozaki T, Asano Y . Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69: 639–642; discussion 42–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Lin TY, Huang YC, Ning HC, Hsueh C . Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16: 1162–1165.

    CAS  PubMed  Google Scholar 

  126. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993; 92: 219–222.

    CAS  PubMed  Google Scholar 

  127. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185–192.

    CAS  PubMed  Google Scholar 

  128. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ . Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988; 85 (2A): 99–101.

    CAS  PubMed  Google Scholar 

  129. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA . Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800–1805.

    CAS  PubMed  PubMed Central  Google Scholar 

  130. Hardy I, Gershon AA, Steinberg SP, LaRussa P . The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325: 1545–1550.

    CAS  PubMed  Google Scholar 

  131. Gershon AA, LaRussa P, Hardy I, Steinberg S, Silverstein S . Varicella vaccine: the American experience. J Infect Dis 1992; 166 (Suppl 1): S63–S68.

    PubMed  Google Scholar 

  132. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P . Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381–383.

    CAS  PubMed  Google Scholar 

  133. Leung AY, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY et al. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 661–665.

    CAS  PubMed  Google Scholar 

  134. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578–585.

    CAS  PubMed  Google Scholar 

  135. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26–34.

    PubMed  Google Scholar 

  136. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS . Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA 1982; 247: 2132–2135.

    CAS  PubMed  Google Scholar 

  137. Balfour Jr HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448–1453.

    PubMed  Google Scholar 

  138. Meyers JD, Wade JC, Shepp DH, Newton B . Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984; 37: 571–574.

    CAS  PubMed  Google Scholar 

  139. Shepp DH, Dandliker PS, Meyers JD . Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208–212.

    CAS  PubMed  Google Scholar 

  140. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ . Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341–347.

    CAS  PubMed  Google Scholar 

  141. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 (Suppl 1): S1–S26.

    CAS  PubMed  Google Scholar 

  142. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G . A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1989; 4: 613–615.

    CAS  PubMed  Google Scholar 

  143. Wutzler P, De Clercq E, Wutke K, Farber I . Oral brivudin vs intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995; 46: 252–257.

    CAS  PubMed  Google Scholar 

  144. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL . A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19: 13–22.

    CAS  PubMed  Google Scholar 

  145. Reusser P . Challenges and options in the management of viral infections after stem cell transplantation. Support Care Cancer 2002; 10: 197–203.

    PubMed  Google Scholar 

  146. Hatchette T, Tipples GA, Peters G, Alsuwaidi A, Zhou J, Mailman TL . Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatr Infect Dis J 2008; 27: 75–77.

    PubMed  Google Scholar 

  147. Peniket AJ, Perry AR, Williams CD, MacMillan A, Watts MJ, Isaacson PG et al. A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 22: 307–309.

    CAS  PubMed  Google Scholar 

  148. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.

    CAS  PubMed  Google Scholar 

  149. Hale G, Waldmann H . Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH users. Blood 1998; 91: 3079–3083.

    CAS  PubMed  Google Scholar 

  150. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C et al. The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059–1067.

    PubMed  Google Scholar 

  151. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880.

    CAS  PubMed  PubMed Central  Google Scholar 

  152. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648–1655.

    CAS  PubMed  Google Scholar 

  153. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell—depleted SCT. Blood 2001; 98: 972–978.

    CAS  PubMed  Google Scholar 

  154. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.

    CAS  PubMed  Google Scholar 

  155. Lankester AC, van Tol MJ, Vossen JM, Kroes AC, Claas E . Epstein–Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002; 99: 2630–2631.

    CAS  PubMed  Google Scholar 

  156. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM . Quantitative analysis of circulating cell-free Epstein–Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000; 111: 239–246.

    CAS  PubMed  Google Scholar 

  157. Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE et al. Epstein–Barr Virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 2006; 1: 17.

    PubMed  PubMed Central  Google Scholar 

  158. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981.

    CAS  PubMed  Google Scholar 

  159. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364–4369.

    CAS  PubMed  Google Scholar 

  160. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K . Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis 2007; 39: 235–244.

    CAS  PubMed  Google Scholar 

  161. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256–269.

    PubMed  Google Scholar 

  162. Powell JL, Bunin NJ, Callahan C, Aplenc R, Griffin G, Grupp SA . An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004; 33: 651–657.

    CAS  PubMed  PubMed Central  Google Scholar 

  163. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N et al. Reconstitution of the Epstein–Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003; 102: 839–842.

    CAS  PubMed  Google Scholar 

  164. Liu D, Tammik C, Zou JZ, Ernberg I, Masucci MG, Ringden O et al. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein–Barr virus load in the peripheral blood of bone marrow transplant recipients. Clin Transplant 2004; 18: 518–524.

    PubMed  Google Scholar 

  165. Cohen JM, Sebire NJ, Harvey J, Gaspar HB, Cathy C, Jones A et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007; 110: 2209–2214.

    CAS  PubMed  Google Scholar 

  166. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–233.

    PubMed  Google Scholar 

  167. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE . Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.

    CAS  PubMed  Google Scholar 

  168. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555.

    CAS  PubMed  Google Scholar 

  169. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.

    CAS  PubMed  Google Scholar 

  170. van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814–821.

    CAS  PubMed  Google Scholar 

  171. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E . Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285.

    CAS  PubMed  Google Scholar 

  172. Hanel M, Fiedler F, Thorns C . Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001; 24: 491–494.

    CAS  PubMed  Google Scholar 

  173. Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F et al. Epstein–Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006; 47: 167–169.

    CAS  PubMed  Google Scholar 

  174. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123–1131.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

KNW acknowledges funding from the National Institute for Health Research through the University College London/University College London Hospitals Comprehensive Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to D Engelhard.

Additional information

A Joint Project of the European Organization for Research and Treatment of Cancer-Infectious Diseases Group, European Bone Marrow Transplantation-Infectious Diseases Working Party, European Leukemia Net-Supportive Care Working Group and of the International Immunocompromised Host Society.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Styczynski, J., Reusser, P., Einsele, H. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43, 757–770 (2009). https://doi.org/10.1038/bmt.2008.386

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.386

Keywords

This article is cited by

Search

Quick links